Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 18, 2024
Iatrogenic myelodysplastic syndrome complicating multiple sclerosis: A case report.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 09, 2024
A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.
Journal: Neurodegenerative disease management
Published: August 03, 2023
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 04, 2023
Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders.
Journal: Journal of the neurological sciences
Published: December 21, 2022
The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 22, 2020
Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study.
Journal: Journal of neurology
Published: December 12, 2019
Treatment of natalizumab-associated PML with filgrastim.
Journal: Annals of clinical and translational neurology
Published: November 21, 2018
Glioblastoma in natalizumab-treated multiple sclerosis patients.
Journal: Annals of clinical and translational neurology
Published: March 03, 2017
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program.
Journal: Neurology and therapy
Published: April 07, 2016
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Journal: BMC neurology
Published: October 25, 2015
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Journal: European journal of neurology
Published: June 04, 2015
Last Updated: 09/26/2026